Steve Liapis

Steve Liapis, Ph.D., is a seasoned professional in the biotechnology and pharmaceutical sectors, currently serving as Director and Principal at Northpond Ventures since November 2021. Liapis holds multiple board member positions at various innovative companies, including Garuda Therapeutics, Kyverna Therapeutics, Totus Medicines, Incendia Therapeutics, and Opna Bio, focusing on transformative therapies for blood stem cells, autoimmune diseases, and cancer. Previously, Liapis held leadership roles at Sanofi, where responsibility included oncology portfolio strategy, and Arbor Biotechnologies, overseeing corporate development and strategy. Liapis has extensive consulting experience from L.E.K. Consulting, managing significant biotech engagements, and academic credentials from Harvard University, where research contributed to advancements in molecular biology.